Literature DB >> 12182689

Tolerability of hypnosedatives in older patients.

Udo Wortelboer1, Stefan Cohrs, Andrea Rodenbeck, Eckart Rüther.   

Abstract

Sleep disturbances are common and prevalence rates increase with age. Especially in the elderly, somatic diseases and medications with adverse effects relating to sleep are frequent reasons for disturbed and nonrefreshing sleep. It should be emphasised that these reasons must be excluded before symptomatic therapy is started. In some cases the use of hypnosedatives may be included as part of the treatment of a somatic disease and may cause sleep disturbances. Pharmacotherapy is one of the main approaches in the management of primary insomnia and should be part of a broader treatment strategy including nonpharmacological methods. This article focuses on the tolerability of frequently prescribed hypnosedatives in the elderly with primary insomnia and addresses the primary care physician. In general, recommendations for the pharmacotherapy of insomnia in elderly patients include using a reduced dosage. For some substances (e.g. zolpidem, zopiclone, zaleplon, temazepam and triazolam) the recommended dosage is half that recommended for younger patients. The properties of the selected hypnosedative should be taken into consideration and matched with the type of sleep disturbance experienced by the patient. Ultrashort-acting drugs may be useful when initiating sleep is the main problem, whereas short- and intermediate-acting substances are recommended for maintaining sleep. Possible interactions with pre-existing medication must also be taken into consideration. Some agents such as antipsychotics, antidepressants, melatonin and herbal agents may be used in specific indications. However, only a few of these substances have proven tolerability in the elderly and further investigations are recommended.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12182689     DOI: 10.2165/00002512-200219070-00006

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  63 in total

Review 1.  The safety and tolerability of zolpidem--an update.

Authors:  G Darcourt; D Pringuey; D Sallière; J Lavoisy
Journal:  J Psychopharmacol       Date:  1999       Impact factor: 4.153

2.  Dose response effects of zolpidem in normal geriatric subjects.

Authors:  M B Scharf; D W Mayleben; M Kaffeman; R Krall; R Ochs
Journal:  J Clin Psychiatry       Date:  1991-02       Impact factor: 4.384

Review 3.  Polysomnographic effects of hypnotic drugs. A review.

Authors:  L Parrino; M G Terzano
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

Review 4.  Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia.

Authors:  J Wagner; M L Wagner; W A Hening
Journal:  Ann Pharmacother       Date:  1998-06       Impact factor: 3.154

Review 5.  [Phytopharmaceutic drugs in treatment of sleep disorders].

Authors:  A Nachtmann; G Hajak
Journal:  Internist (Berl)       Date:  1996-07       Impact factor: 0.743

6.  [Sleep complaints and hypnotic use by the elderly--results of a representative survey in West Germany].

Authors:  S Simen; A Rodenbeck; G Schlaf; K Müller-Popkes; G Hajak
Journal:  Wien Med Wochenschr       Date:  1996

Review 7.  Adjunctive therapy in patients with Alzheimer's disease. A practical approach.

Authors:  J Corey-Bloom; D Galasko
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

8.  Zolpidem for dementia-related insomnia and nighttime wandering.

Authors:  P S Shelton; L B Hocking
Journal:  Ann Pharmacother       Date:  1997-03       Impact factor: 3.154

9.  Evaluation of severe insomnia in the general population: results of a European multinational survey.

Authors:  H Chevalier; F Los; D Boichut; M Bianchi; D J Nutt; G Hajak; J Hetta; G Hoffmann; C Crowe
Journal:  J Psychopharmacol       Date:  1999       Impact factor: 4.153

Review 10.  Insomnia in the elderly: a review for the primary care practitioner.

Authors:  S Ancoli-Israel
Journal:  Sleep       Date:  2000-02-01       Impact factor: 5.849

View more
  7 in total

1.  A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers.

Authors:  Ian Hindmarch; Eric Legangneux; Neil Stanley; Steve Emegbo; Jean Dawson
Journal:  Br J Clin Pharmacol       Date:  2006-11       Impact factor: 4.335

Review 2.  Use of sleep-promoting medications in nursing home residents : risks versus benefits.

Authors:  David K Conn; Robert Madan
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease.

Authors:  Heidi Taipale; Anna-Maija Tolppanen; Marjaana Koponen; Antti Tanskanen; Piia Lavikainen; Reijo Sund; Jari Tiihonen; Sirpa Hartikainen
Journal:  CMAJ       Date:  2017-04-10       Impact factor: 8.262

4.  Sleep in the Elderly: Burden, Diagnosis, and Treatment.

Authors:  W Vaughn McCall
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

5.  Insomnia in general practice : a consensus report produced by sleep specialists and primary-care physicians in Italy.

Authors:  Mario Giovanni Terzano; Liborio Parrino; Enrica Bonanni; Fabio Cirignotta; Franco Ferrillo; Gian Luigi Gigli; Mariantonietta Savarese; Luigi Ferini-Strambi
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 6.  Use of non-benzodiazepine hypnotics in the elderly: are all agents the same?

Authors:  Christian Dolder; Michael Nelson; Jonathan McKinsey
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 7.  Cognitive and balance dysfunctions due to the use of zolpidem in the elderly: a systematic review.

Authors:  Guilherme Tavares; Gizela Kelmann; Francisco Tustumi; Catherine Nardini Tundisi; Bárbara Regina Bruço Silveira; Bruno Maximiliano Augusto Colombo Barbosa; Diana Bragança Winther; Eduarda Conte Boutros; Gabriel Dos Santos Villar; Giovanna Brunocilla; Gustavo Rodrigues Caldas Lourenção; Jiulia Giovanna Aranha Ferreira; Wanderley Marques Bernardo
Journal:  Dement Neuropsychol       Date:  2021 Jul-Sep
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.